tirzepatide and hypertension blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial Is Tirzepatide Better Than Semaglutide

Wegovy pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in Phase III trials, boasting an average weight loss of about 17%, when used along with a reduced-calorie diet and exercise and if all patients stayed on treatment, compared to about three per cent for placebo

Protein optimization Adequate protein intake produces measurable appetite suppression through multiple mechanisms: increased satiety hormones (including GLP-1 and PYY), higher thermic effect of food, and preservation of lean mass during weight loss

Orforglipron (Foundayo) has been approved for use in the US, but is still awaiting UK approval by the MHRA

Simply take your next scheduled dose at the regular time rather than doubling up